Effects of co-administration of bupropion and nicotinic agonists on the elevated plus-maze test in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 3, 2006, Pages 455-462

  Carrasco, M Carmen ^a   Vicens, Paloma ^b   Vidal, Jose ^a   Redolat, Rosa ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Anxiety; Bupropion; Cytisine; Lobeline; Mice; Nicotine; Plus maze

Indexed keywords

AMFEBUTAMONE; CYTISINE; LOBELINE; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BODY POSTURE; DRUG EFFECT; MALE; MAZE TEST; MOUSE; NONHUMAN; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BUPROPION; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; MALE; MAZE LEARNING; MICE; NICOTINIC AGONISTS;

EID: 33646494220     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.11.018     Document Type: Article

References (78)

1. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56 (1995) 395-401
2. Barros D.M., Izquierdo L.A., Medina J.H., and Izquierdo I. Bupropion and sertraline enhance retrieval of recent and remote long-term memory in rats. Behav Pharmacol 13 (2002) 215-220
3. Bernal M.C., Vicens P., Carrasco M.C., and Redolat R. Effects of nicotine on spatial learning in C57BL mice. Behav Pharmacol 10 (1999) 333-336
4. Bhat R.V., Marks J.M., and Collins A.C. Effects of chronic nicotine infusion on kinetics of high-affinity nicotine binding. J Neurochem 62 (1991) 574-581
5. Boido C.C., Tasso B., Boido V., and Sparatore F. Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities. Il Farmaco 58 (2003) 265-277
6. Brioni J.D., O'Neill A.B., Kim D.J., and Decker M.W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol 238 (1993) 1-8
7. Carrasco M.C., Vicens P., Vidal J., and Redolat R. Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice. Prog Neuro-Psychopharmacol Biol Psychiatry 28 (2004) 1135-1141
8. Chandler C.J., and Stolerman I.P. Discriminative stimulus properties of the nicotinic agonist cytisine. Psychopharmacology 129 (1997) 257-264
9. Cheeta S., Irvine E.E., Kenny P.J., and File S.E. The dorsal raphé nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses. Psychopharmacology 155 (2001) 78-85
10. Cooper B.R., Hester T.J., and Maxwell R.A. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215 (1980) 127-134
11. Damaj M.I., Carroll F.I., Eaton J.B., Navarro H.A., Blough B.E., Mirza S., et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66 (2004) 675-682
12. Decker M.V., Brioni J.D., Bannon A.W., and Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci 56 (1995) 545-570
13. Dwoskin L.P., and Crooks P.A. Competitive neural nicotinic receptor antagonist: a new direction for drug discovery. J Pharmacol Exp Ther 298 (2001) 395-402
14. Dwoskin L.P., and Crooks P.A. A novel mechanism of action and potential use for lobeline as a treatment of psychostimulant abuse. Biochem Pharmacol 63 (2002) 89-98
15. Espejo E.F. Structure of the mouse behavior on the elevated plus-maze test of anxiety. Behav Brain Res 86 (1997) 105-112
16. Eyerman D.J., and Yamamoto B.K. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J Pharmacol Exp Ther 312 (2005) 160-169
17. Felpin F., and Lebreton J. History, chemistry and biology of alkaloids from Lobelia inflate. Tetrahedron 60 (2004) 10127-10153
18. Ferris R.M., Cooper B.R., and Maxwell R.A. Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry 44 (1983) 74-78
19. File S.E., Kenny P.J., and Cheeta S. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol Biochem Behav 66 (2000) 65-72
20. File S.E., Kenny P.J., and Ouagazzal A.M. Bimodal modulation by nicotine of anxiety in the social interaction test: role of dorsal hippocampus. Behav Neurosci 112 (1998) 1423-1429
21. Fryer J.D., and Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine and ibogaine. J Pharmacol Exp Ther 288 (1999) 88-92
22. Fudala P., and Iwamoto E. Further studies on nicotine-induced conditioned place preference in the rat. Pharmacol Biochem Behav 25 (1986) 1041-1049
23. Harrod S.B., Dwoskin P.L., and Bardo M.T. Lobeline produces conditioned taste avoidance in rats. Pharmacol Biochem Behav 78 (2004) 1-5
24. Harrod S.B., Dwoskin P.L., Green T.A., Gehrke B.J., and Bardo M.T. Lobeline does not serve as a reinforcer in rats. Pychopharmacology 165 (2003) 397-404
25. Hasegawa H., Meeusen R., Sarre S., Diltoer M., Piacentini M.F., and Michotte Y. Acute dopamine/noradrenaline reuptake inhibition increases brain and core temperature in rats. J Appl Physiol 99 (2005) 1397-1401
26. Hays J.T., and Ebbert J.O. Bupropion for the treatment of tobacco dependence. Guidelines for balancing risks and benefits. CNS Drugs 17 (2003) 71-83
27. Hughes J.R., Stead L.F., and Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 4 (2004) CD000031
28. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs 62 (2002) 25-35
29. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 (1999) 685-691
30. Klimek V., Nowak G., and Czyrak A. Central effects of repeated treatment with bupropion. Pol J Pharmacol Phar 37 (1985) 243-252
31. Lake J.R., Montellano A.L., Presley S.E., Meyer-Paal R.L., Perales B.A., Oliver M., et al. Acute-bupropion dose-dependently reduces nicotine abstinence syndrome in the rat. Soc Neurosci Abstr 27 (2001) 15 [Program No 572]
32. Learned-Coughlin S.M., Bergstrom M., Savitcheva I., Ascher J., Schmith V.D., and Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 54 (2003) 800-805
33. Lecca D., Shim I., Costa E., and Javaid J.I. Striatal application of nicotine, but not of lobeline, attenuates dopamine release in freely moving rats. Neuropharmacology 39 (2000) 88-98
34. Levin E.D., and Christopher C.N. Lobeline-induced learning improvement of rats in the radial-arm maze. Pharmacol Biochem Behav 76 (2003) 133-139
35. Li S.X., Perry K.W., and Wong D.T. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42 (2002) 181-190
36. Lim D.Y., Kim Y.S., and Miwa S. Influence of lobeline on catecholamine release from the isolated perfused rat adrenal gland. Auton Neurosci 110 (2004) 27-35
37. + efflux from thalamic synaptosomes. Neuropharmacology 39 (2000) 2654-2662
38. Miller D.K., Crook P.A., Teng L., Witkin J.M., Munzar P., Goldberg S.R., et al. Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J Pharmacol Exp Ther 296 (2001) 1023-1034
39. Miller D.K., Crooks P.A., Zheng G., Grinevich V.P., Norrholm S.D., and Dwoskin L.P. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther 310 (2004) 1035-1045
40. Miller D.K., Harrod S.B., Green T.A., Wong M., Bardo M.T., and Dwoskin L.P. Lobeline attenuates stimulation induced by repeated nicotine administration in rats. Pharmacol Biochem Behav 74 (2003) 279-286
41. 3H] norepinephrine. J Pharmacol Exp Ther 302 (2002) 1113-1122
42. Moragrega I., Carrasco M.C., Vicens P., and Redolat R. Spatial learning in male mice with different levels of aggressiveness: effects of housing condicitons and nicotine administration. Behav Brain Res 147 (2003) 1-8
43. Muley M.P., Joshi M.A., and Manekar M.S. Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice. J Pharmacol 36 (1984) 208-210
44. Nakagawa T., Ukai K., Ohyama T., Gomita Y., and Okamura H. Effects of dopaminergic agents on reversal of reserpine-induced impairment in conditioned avoidance response in rats. Pharmacol Biochem Behav 58 (1997) 829-836
45. A receptors which contains the alpha-5 subunit, in the elevated plus-maze test. Prog Neuro-psychopharmacol Biol Psychiatry 26 (2002) 1389-1392
46. Nuutinen S., Ahtee L., and Tuominen R.K. Time and brain region specific up-regulation of low affinity neuronal nicotinic receptors during chronic nicotine administration in mice. Eur J Pharmacol 515 (2005) 83-89
47. O'Neill A.B., and Brioni J.D. Benzodiacepine receptor mediation of anxiolytic-like effect of (-)-nicotine in mice. Pharmacol Biochem Behav 49 (1994) 755-777
48. Pellow S., and File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24 (1986) 525-529
49. Picciotto M.R., Brunzell D.H., and Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 13 (2002) 1097-1106
50. Rauhut A.S., Dwoskin L.P., and Bardo M.T. Bupropion dose-dependently and selectively increases nicotine self-administration in rats. Drug Alcohol Depend 66 (2002) S144
51. Reavill C., Walther B., Stolerman I.P., and Testa B. Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 29 (1990) 619-624
52. Redolat R., Gomez M.C., Moragrega I., Spitalnick E., and Carrasco M.C. Bupropion influences active-avoidance learning in NMRI mice. Proceedings of the 6th Annual Conference of the Society for Research on Nicotine and Tobacco (2004)
53. Redolat R., Gomez M.C., Vicens P., and Carrasco M.C. Bupropion effects on aggressiveness and anxiety in OFI male mice. Psychopharmacology 177 (2005) 418-427
54. Redolat R., Oterino M.C., Carrasco M.C., Berry M.S., and Brain P.F. Effects of acute administration of nicotine and lobeline on agonistic encounters in male mice. Aggress Behav 26 (2000) 376-385
55. Redolat R., Oterino M.C., Carrasco M.C., and Brain P.F. Repeated administration of lobeline has a specific antiaggressive effect. Addict Biol 7 (2002) 301-306
56. Redolat R., Vidal J., Gomez M.C., and Carrasco M.C. Effects of acute bupropion administration on locomotor activity in adolescent and adult mice. Behav Pharmacol 16 (2005) 59-62
57. Richmond R., and Zwar N. Review of bupropion for smoking cessation. Drug Alcohol Rev 22 (2003) 203-220
58. Rodgers R.J., and Cole J.C. Influence of social isolation, gender, strain and prior novelty on plus-maze behaviour in mice. Physiol Behav 54 (1993) 729-736
59. Rodgers R.J., and Cole J.C. The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper S.J., and Hendrie C.A. (Eds). Ethology and psychopharmacology (1994), John Wiley, Chichester 9-44
60. Rodgers R.J., Johnson N.J.T., Carr J., and Hodgson T.P. Resistance of experientally-induced changes in murine plus-maze behaviour to altered retest conditions. Behav Brain Res 86 (1997) 71-77
61. Salas R., Pieri F., Fung B., Dani J.A., and De Biasi M. Altered anxiety-related responses in mutant mice lacking the subunited of the nicotinic receptor. J Neurosci 23 (2003) 6255-6263
62. Shoaib M., Sidhpura N., and Shafait S. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology 165 (2003) 405-412
63. Shoaib M., Stolerman I.P., and Kumar R.C. Nicotine-induced place preference following prior exposure in rats. Psychopharmacology 113 (1994) 445-452
64. Singh A., Potter A., and Newhouse P. Nicotinic acetylcholine receptor system and neuropsychiatric disorders. Drugs 7 (2004) 1096-1103
65. Slemmer J.E., Martin B.R., and Damaj M.I. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295 (2000) 321-327
66. Stahl S.M., Pradko J.F., Haight B.R., Modell J.G., Rockett C.B., and Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiat 6 (2004) 159-166
67. Stolerman I.P., Garch H.S., and Mirza N.R. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychoparmacology 117 (1995) 430-437
68. Terry A.V., Williamson R., Gattu M., Beach J.W., McCurdy C.R., Sparks J.A., et al. Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Neuropharmacology 37 (1998) 93-102
69. Vicens P., Bernal M.C., Carrasco M.C., and Redolat R. Effects of lobeline on spatial learning in C57BL mice. Neurosci Res Commun 27 (2000) 9-19
70. Vicens P., Carrasco M.C., and Redolat R. Effects of early training and nicotine treatment on the performance of male NMRI mice in the water maze. Neural Plast 10 (2003) 303-317
71. Wall P.M., and Messier C. Ethological confirmatory factor analysis of anxiety-like behaviour in the murine elevated plus-maze. Behav Brain Res 114 (2000) 199-212
72. Young R., and Glennon R.A. Nicotine and bupropion share a similar discriminative stimulus effect. Eur J Pharmacol 443 (2002) 113-118
73. Zarrindast M.R., and Abolfathi-Araghi F. Effects of bupropion on core body temperature of mice. Psychopharmacology 106 (1992) 248-252
74. Zarrindast M.R., Hodjati M.R., Pejhan A., and Soleimannejad E. Bupropion induces sniffing: a possible dopaminergic mechanism. Eur Neuropsychopharmacol 6 (1996) 299-303
75. Zarrindast M.R., and Hosseini-Nia T. Anorectic and behavioural effects of bupropion. Gen Pharmacol 19 (1988) 201-204
76. Zarrindast M.R., Khajenabi Y., and Pourgholami M.H. Bupropion-induced climbing through D-1 and D-2 dopamine receptor activation. Med J Islam Repub Iran 6 (1993) 285-289
77. Zarrindast M., Momayoun H., Babaie A., Etminani A., and Gharib B. Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice. Eur J Pharmacol 407 (2000) 145-158
78. B receptor stimulation induces antianxiety profile in rats. Pharmacol Biochem Behav 69 (2001) 9-15